Fulcrum Therapeutics, Inc.

By person

22 insiders · 98 transactions

1.0×

Alex C. Sapir holds only 1.0 times base salary in stock. $680.63K of shares against $650.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Alex C. Sapir last reported holding, valued at $3.52, the price Common Stock was last bought or sold at on the open market here, on 17 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

RA CAPITAL MANAGEMENT, L.P. entity

10% owner

$40.00M (8)

$58.38M (3)

−$18.38M

6,053,960

$21.31M

−57.1%

Gould Robert J

Director

—

$4.94M (29) scheduled

−$4.94M

454,864

$1.60M

−18.4%

Casdin Capital, LLC entity

10% owner

$2.22M (3)

—

+$2.22M

604,285

$2.13M

—

6 Dimensions Capital, L.P. entity

10% owner

$1.90M (1)

—

+$1.90M

559,821

$1.97M

—

Sanofi

10% owner

$1.50M (1)

—

+$1.50M

558,035

$1.96M

—

TANG KEVIN

10% owner

$1.49M (6)

—

+$1.49M

7,080,945

$24.92M

+6.3%

LEVIN MARK J

Director

$1.30M (1)

—

+$1.30M

9,924,404

$34.93M

+58.8%

Third Rock Ventures III, L.P. entity

10% owner

$1.30M (1)

—

+$1.30M

1,962,202

$6.91M

+586.8%

Third Rock Ventures IV, L.P. entity

10% owner

$1.30M (1)

—

+$1.30M

2,343,154

$8.25M

—

Stuart Bryan

See Remarks

—

$1.23M (2) scheduled

−$1.23M

$0.00

—

Moxham Christopher

Chief Scientific Officer

—

$911.42K (2) scheduled

−$911.42K

31,071

$109.37K

0.0%

Sapir Alex

See Remarks

$492.03K (1)

—

+$492.03K

193,360

$680.63K

—

Thomson Peter G.

VP Finance & Accounting

$20.70K (1)

$456.33K (8)

−$435.63K

17,512

$61.64K

−55.5%

Wallace Owen B.

Chief Scientific Officer

—

$245.44K (6) scheduled

−$245.44K

133,438

$469.70K

+5.0%

Cadavid Diego

SVP Clinical Development

—

$205.75K (13) scheduled

−$205.75K

65,714

$231.31K

−7.5%

GERAGHTY JAMES A

Director

$91.60K (1)

—

+$91.60K

90,714

$319.31K

+12.4%

Ezekowitz Alan

Director

—

$65.61K (1)

−$65.61K

10,927

$38.46K

−62.2%

Tourangeau Greg

Principal Accounting Officer

—

$62.26K (4)

−$62.26K

14,062

$49.50K

−15.5%

Oltmans Curtis Gale

Chief Legal Officer

$9.80K (1)

$44.60K (1)

−$34.80K

10,252

$36.09K

−18.7%

Morabito Christopher

Chief Medical Officer

$10.08K (1)

—

+$10.08K

1,100

$3.87K

—

GSK plc entity

10% owner

—

1,785,714

$6.29M

—

Section 32 Fund 2, LP entity

10% owner

—

464,285

$1.63M

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

Insider

Date

Role

Action

Price

Amount

Ezekowitz Alan

26 Jun 2026

Director

Sell

18,000

$3.65

$65.61K

Gould Robert J

2 Feb 2026

Director

Sell

15,000

$10.72

$160.86K

Gould Robert J

2 Jan 2026

Director

Sell

15,000

$11.87

$178.09K

Oltmans Curtis Gale

15 Dec 2025

Chief Legal Officer

Sell

3,452

$12.92

$44.60K

RA CAPITAL MANAGEMENT, L.P.

8 Dec 2025

10% owner

Sell indirect

91,722

$14.98

$1.37M

RA CAPITAL MANAGEMENT, L.P.

8 Dec 2025

10% owner

Sell indirect

2,706,397

$14.28

$38.65M

RA CAPITAL MANAGEMENT, L.P.

8 Dec 2025

10% owner

Sell indirect

1,377,020

$13.33

$18.36M

Gould Robert J

19 Nov 2025

Director

Sell

15,000

$11.03

$165.50K

Tourangeau Greg

8 May 2025

Principal Accounting Officer

Sell

498

$5.06

$2.52K

Tourangeau Greg

7 May 2024

Principal Accounting Officer

Sell

236

$7.76

$1.83K

Tourangeau Greg

8 Mar 2024

Vice President, Finance

Sell

4,884

$11.72

$57.22K

Tourangeau Greg

10 May 2023

Principal Accounting Officer

Sell

210

$3.31

$695.10

Gould Robert J

13 Jan 2023

Interim President & CEO

Sell

6,766

$15.00

$101.49K

Gould Robert J

16 Mar 2021

See Remarks

Sell

789

$12.43

$9.81K

Gould Robert J

15 Mar 2021

See Remarks

Sell

9,211

$12.13

$111.77K

Gould Robert J

16 Feb 2021

See Remarks

Sell

1,673

$14.56

$24.37K

Gould Robert J

16 Feb 2021

See Remarks

Sell

6,542

$14.19

$92.83K

Thomson Peter G.

21 Jan 2021

VP Finance & Accounting

Sell

6,607

$14.00

$92.50K

Gould Robert J

20 Jan 2021

See Remarks

Sell

10,000

$12.08

$120.83K

Gould Robert J

8 Jul 2020

See Remarks

Sell

2,500

$20.00

$50.00K

Cadavid Diego

1 Jul 2020

SVP Clinical Development

Sell

1,071

$18.30

$19.60K

Gould Robert J

25 Jun 2020

See Remarks

Sell

2,500

$20.80

$51.99K

Gould Robert J

9 Jun 2020

See Remarks

Sell

156

$20.00

$3.12K

Gould Robert J

5 Jun 2020

See Remarks

Sell

3,433

$20.17

$69.25K

Gould Robert J

4 Jun 2020

See Remarks

Sell

1,300

$20.04

$26.06K

Gould Robert J

3 Jun 2020

See Remarks

Sell

1,500

$20.13

$30.19K

Gould Robert J

2 Jun 2020

See Remarks

Sell

2,797

$20.00

$55.94K

Gould Robert J

1 Jun 2020

See Remarks

Sell

$20.00

$100.00

Gould Robert J

29 May 2020

See Remarks

Sell

1,390

$20.08

$27.91K

Gould Robert J

28 May 2020

See Remarks

Sell

1,919

$20.01

$38.39K

Gould Robert J

26 May 2020

See Remarks

Sell

2,500

$20.00

$50.00K

Thomson Peter G.

11 May 2020

VP Finance & Accounting

Sell

7,500

$16.00

$120.00K

Cadavid Diego

2 Mar 2020

SVP Clinical Development

Sell

315

$18.13

$5.71K

Cadavid Diego

2 Mar 2020

SVP Clinical Development

Sell

1,828

$17.26

$31.55K

Thomson Peter G.

24 Feb 2020

VP Finance & Accounting

Sell

250

$18.61

$4.65K

Thomson Peter G.

24 Feb 2020

VP Finance & Accounting

Sell

2,102

$17.43

$36.64K

Thomson Peter G.

24 Feb 2020

VP Finance & Accounting

Sell

2,648

$16.18

$42.86K

Gould Robert J

19 Feb 2020

See Remarks

Sell

2,500

$20.00

$50.00K

Cadavid Diego

3 Feb 2020

SVP Clinical Development

Sell

2,143

$17.33

$37.14K

Thomson Peter G.

23 Jan 2020

VP Finance & Accounting

Sell

262

$18.05

$4.73K

Thomson Peter G.

23 Jan 2020

VP Finance & Accounting

Sell

4,738

$17.17

$81.37K

Show all 98 transactions →

Fulcrum Therapeutics, Inc.

By person

Individual transactions

What was left out